MERAIODE: A Redifferentiation Phase II Trial With Trametinib and Dabrafenib Followed by Radioactive Iodine Administration for Metastatic Radioactive Iodine Refractory Differentiated Thyroid Cancer Patients With a BRAFV600E Mutation (NCT 03244956)

Background: Two-thirds of patients with metastatic differentiated thyroid cancer (DTC) become refractory to radioactive iodine (RAIR). The inhibition of the MAP-kinase pathway that is activated in case of BRAFV600E mutation might increase RAI incorporation into metastatic foci and reverse the RAI re...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Endocr Soc
Hlavní autoři: Leboulleux, Sophie, Cao, Christine Do, Zerdoud, Slimane, Attard, Marie, Bournaud, Claire, Benisvy, Danielle, Taieb, David, Bardet, Stephane, Terroir-Cassou-Mounat, Marie, Betrian, Sarah, Lion, Georges, Schiazza, Aurelie, Sajous, Christophe, Garcia, Marie-Eve, Schlumberger, Martin Jean, Godbert, Yann, Borget, Isabelle
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2021
Témata:
Thyroid
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8089684/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.1789
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky